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S U M M A R Y
Mycobacterium celatum is a rare cause of human infection, causing disseminated disease in
immunosuppressed individuals. Infections localized to the lungs and the lymph nodes have also been
reported in immunocompetent individuals. The existing literature on the subject is limited as are
experiences with treatment regimens and durations. In the case presented herein, two different
treatment regimens were applied to an immunocompromised HIV-negative patient with primary skin
involvement and extensive pulmonary involvement due to suspected relapse on isoniazid, ethambutol,
and clarithromycin treatment. The treatment regimen was changed to azithromycin, ciproﬂoxacin, and
pyrazinamide and the treatment duration was prolonged to a total of 24 months, with good effect.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Mycobacterium celatum is a slow-growing acid-fast bacillus that
was ﬁrst identiﬁed in 1993.1 Its clinical presentation mimics that of
Mycobacterium tuberculosis and the identiﬁcation of M. celatum
typically requires molecular testing. It is a rare cause of infection in
humans that has been reported to cause localized infections in the
lungs and the lymph nodes, as well as disseminated disease, the
latter only seen in immunosuppressed individuals. The existing
literature on the subject is limited and so are experiences with
treatment regimens. In this case report, two different treatment
regimens were used on a patient with primary skin involvement as
well as extensive pulmonary involvement, and a long treatment
was indicated.
2. Case report
A 70-year-old female presented with fatigue, dyspnea on
exertion, a slightly productive cough, and an abscess on the right
forearm with a ﬂuctuating mass. Mycobacterial culture of the
abscess showed M. celatum, identiﬁed by GenoType Mycobacteri-
um AS (Hain Lifescience, Nehren, Germany). A computed* Corresponding author. Tel.: +245 54 54 615.
E-mail address: ceciliepatsche@live.dk (C.B. Patsche).
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license (http://creativecommons.org/licenses/by-nc-sa/3.0/).tomography (CT) scan revealed multiple enlarged lymph nodes
in the axillae, periclavicular and mediastinal areas, along with
splenomegaly and bullae in the lungs. A positron emission
tomography (PET)-CT scan showed activity corresponding to the
right lung parenchyma, upper and lower lobe, and both shoulders,
including a previous fracture in the left shoulder (Figure 1). As part
of the initial work-up, a bone marrow examination was done; this
was normal. Histopathology was done on abscess material from
the forearm and an enlarged axillary lymph node; only inﬂamma-
tion was found in the abscess material and no granuloma or
malignancy was found in the lymph node. Acid-fast bacteria were
found on microscopy of the abscess ﬂuid, but all later specimens
examined were negative.
After a review of the limited literature on M. celatum and in
accordance with American Thoracic Society (ATS) guidelines,2 it was
decided to commence the following treatment regimen: clarithro-
mycin 500 mg twice daily, isoniazid 300 mg once daily, and
ethambutol 1200 mg once daily for 18 months. The patient suffered
from chronic anemia and had been treated for epilepsy with
lamotrigine and depression with mirtazapine; both conditions were
stable. There was no known exposure to mycobacteria, no previous
history of tuberculosis, and the patient was HIV-negative.
Drug susceptibility testing (DST) of the M. celatum isolate was
initially done on Bactec 460 (BD, Franklin Lakes, NJ, USA) and this
was later re-evaluated using Bactec MGIT (BD) and microdilution
minimum inhibitory concentration (MIC) (TREK Diagnostic Systems,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
C.B. Patsche et al. / International Journal of Infectious Diseases 26 (2014) 88–90 89East Grinstead, UK). The DST results are given in Table 1; our
M. celatum strain tested resistant to rifampin and rifabutin in both
DSTs, was susceptible to isoniazid in the ﬁrst DST, but was resistant
in the second DST. All DSTs were performed in accordance with
the manufacturers’ instructions. There was no method for testing
pyrazinamide susceptibility in non-tuberculous mycobacteria
available in the laboratory.
During treatment, the fatigue and pain resolved and the abscess
on the right forearm, which had continued to secrete for the ﬁrst 2
months, healed completely within 6 months of treatment.
The patient showed signs of both humoral and cellular immunode-
ﬁciency with a severely decreased IgG2 level of 0.27 g/l and CD4 countFigure 1. (A) Images taken in 2010. The CT scans shows enlarged lymph nodes in the axil
The PET-CT shows activity in the right lung parenchyma, upper and lower lobe, and both 
lungs; the sizes of the multiple enlarged lymph nodes are unchanged and new enlarge
Table 1
Bactec 460 and Bactec MGIT (BD) and microdilution MIC of drugs to isolated Mycobact
Drug Bactec 460 Test result Bactec MGIT and m
Ethambutol 2.5 mg/l S 5 
Rifampin 2 mg/l R 1 
Isoniazid 1.0 mg/l S 0.1 and 0.4 
Rifabutin 1.0 mg/l R 0.5 
Clofazimine 1 mg/l S
Oﬂoxacin 2.0 mg/l S 2 
Amikacin 4 mg/l S 1 
Clarithromycin 4 mg/l S 1, 4, 16, and 64 
Moxiﬂoxacin 0.25 
S, susceptible; R, resistant; MIC, minimum inhibitory concentration.of 250 cells/mm3, with a decreased CD4/CD8 ratio and pathological
B-cell phenotype. Yet there was normal total IgG, IgM, and IgA, thus the
patient did not fulﬁll the criteria for a diagnosis of common variable
immunodeﬁciency and was not offered immunoglobulin substitution
treatment. During treatment for M. celatum, the CD4 count increased
to 570 cells/mm3 but IgG2 was low and unchanged and the patient
was diagnosed with idiopathic CD4 lymphopenia and an IgG2
subclass deﬁciency for which no treatment was indicated.
After 15 months of treatment, PET-CT revealed new round
inﬁltrates on both lungs; the sizes of the multiple enlarged lymph
nodes were unchanged and new enlarged lymph nodes had
appeared alongside the iliac vessels (Figure 1). Relapse waslae, periclavicular and mediastinal areas, and splenomegaly and bullae in the lungs.
shoulders. (B) Images taken in 2011. The PET-CT shows new round inﬁltrates in both
d lymph nodes have appeared alongside the iliac vessels.
erium celatum
icrodilution MIC: tested concentration mg/l MIC,
mg/l
Test result
4 S
>8 R
2 R
2 R
– S
1 S
0.06 S
0.12 S
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lavage was negative. Histopathology of bronchoalveolar lavage
ﬂuid was normal, showing slight inﬂammation, and no malignancy
was found. The treatment regimen was changed to azithromycin
500 mg twice daily, ciproﬂoxacin 500 mg twice daily, and
pyrazinamide 2000 mg once daily for an additional 10 months
and hence treatment was prolonged to a total of 24 months. There
was a rapid improvement on this treatment; the cough, fever, and
malaise disappeared, and there was normalization of C-reactive
protein, however the erythrocyte sedimentation rate remained
elevated. This was interpreted as a treatment effect, and after 24
months of treatment the patient felt well and treatment was
therefore discontinued.
At a clinical control 6 months after the discontinuation of
treatment, there were no signs of recurrence of the Mycobacterium
and the patient felt well without any complaints.
3. Discussion
A patient with disseminated M. celatum disease and a primary
immune deﬁciency was treated successfully with a combination
of azithromycin, ciproﬂoxacin, and pyrazinamide. Previous
treatment with clarithromycin, isoniazid, and ethambutol in
accordance with the ATS guidelines2 was unsuccessful. This case
report adds to the sparse clinical data on the treatment of a rare
mycobacterial infection, for which we know little about the
clinical relevance of resistance testing. The clinical course
indicates that the results of susceptibility testing were in
agreement with the ﬁnal treatment outcome and this case adds
to the body of evidence on the treatment of M. celatum. No certain
treatment failure was documented on the ﬁrst treatment regimen,
which has been found to be effective by others and for which there
was in vitro susceptibility. Yet we chose a change of regimen due to
the clinical deterioration and noted improvement following this
change. The modiﬁed treatment regimen was chosen from the
effective salvage regimen used by Piersimoni et al. in a reported
immunocompromised case,3 which involved pyrazinamide. We
chose this regimen in order to be able to keep the patient on an oral
therapy and to change all used drugs. We had no knowledge of
pyrazinamide resistance in this particular case, and although
generally not on the list of recommended drugs in the ATS
guidelines, we chose to use it based on the successful experience
in the Italian case3 and from the general experience and World
Health Organization (WHO) recommendations4 that pyrazinamide
is useful in multidrug-resistant tuberculosis (MDR-TB) despite
possible in vitro resistance.
In a 2004 review by Christiansen et al.,5 19 previous cases of M.
celatum were identiﬁed, of which 15 had occurred in immuno-
suppressed patients. A comparison of treatment regimens revealed
that the M. celatum organism was generally susceptible to
azithromycin, clarithromycin, and ciproﬂoxacin, although some
isolates were reported to be resistant to ciproﬂoxacin. All isolates
were reported to be resistant to rifampin and most to isoniazid.
Although not thoroughly tested, it seemed that most isolates were
susceptible to newer quinolones. Tan et al.6 reached the same
conclusion based on a review of eight previous HIV-negative cases
and also concluded that ethambutol is effective in the treatmentregimen. All but one of the cases in the review improved or were
cured after such treatment. The ATS guidelines2 suggest that
M. celatum is susceptible to isoniazid and rifabutin, which, based
on previous case reports, may not after all be the case.
In the latest reported case of M. celatum, a 25-year old patient’s
congenital cystic adenomatoid malformation in adulthood was
complicated with an M. celatum infection.7 The infection was
treated with ethambutol, rifampin, and clarithromycin, which
was later supplemented with levoﬂoxacin due to low suscepti-
bility to rifampin. The treatment duration was 16 months, with
the patient having a right lung lobectomy 4 months into
treatment.
In another case of M. celatum pulmonary disease in an
immunocompetent 33-year old patient,8 the treatment regimen
was composed of clarithromycin, ethambutol, and ciproﬂoxacin for
1 year. The patient then had a pulmonary resection and the duration
of treatment was prolonged to 2 years. This particular strain was
found to be resistant to isoniazid and rifampin. Both cases had long
treatment durations, and in the present case, the treatment duration
was also prolonged to 24 months due to suspected relapse.
This case adds to the clinical experience that there is often a
discrepancy between the resistance testing results in non-
tuberculous mycobacterial isolates and the clinical response in
the patient, as has been reviewed by Petrini.9 This is important to
be aware of, and therefore it is important that clinical experiences
with these patients are published.
In conclusion, M. celatum is an unusual cause of mycobacterial
disease and there is little clinical knowledge about treatment
options. This case report presents a case of disseminated infection
in an immunocompromised patient with possible relapse on
isoniazid, ethambutol, and clarithromycin treatment, but with a
good response to a treatment regimen consisting of azithromycin,
ciproﬂoxacin, and pyrazinamide.
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